In UTERO Treatment of Cytomegalovirus Congenital Infection With Valacyclovir
Status:
Terminated
Trial end date:
2011-06-01
Target enrollment:
Participant gender:
Summary
The infection with cytomegalovirus (CMV) is the first cause of congenital neurological
handicap of infectious origin. It is probable that the neonatal viral load is correlated with
becoming of infected new-born babies. Among the active antiviral treatments against CMV,
valacyclovir is the only whose fetal and maternal tolerance was evaluated during the
pregnancy. Its harmlessness and its aptitude to decrease the CMV viral load justify to
evaluate it in a study against placebo. Decrease the fetal viral load could make possible to
decrease symptomatology neonatal in a group of infected fetuses.